Stocks and Investing
Stocks and Investing
Wed, February 21, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yatin Suneja Maintained (AXSM) at Strong Buy with Increased Target to $125 on, Feb 21st, 2024
Yatin Suneja of Guggenheim, Maintained "Axsome Therapeutics, Inc." (AXSM) at Strong Buy with Increased Target from $110 to $125 on, Feb 21st, 2024.
Yatin has made no other calls on AXSM in the last 4 months.
There are 5 other peers that have a rating on AXSM. Out of the 5 peers that are also analyzing AXSM, 0 agree with Yatin's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with Yatin
- Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $112 on, Friday, February 16th, 2024
- Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $111 on, Tuesday, February 6th, 2024
- David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $113 on, Tuesday, January 16th, 2024
- Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $180 on, Tuesday, December 26th, 2023
- David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $125 on, Wednesday, December 13th, 2023
Contributing Sources